



FLORIDA SOCIETY OF CLINICAL ONCOLOGY
FLASCO BLAST –October 28, 2009
FLASCO WEBSITE: www.flasco.org
FLASCO CLINICAL TRIALS NETWORK WEBSITE: www.fctn.org

MESSAGE FROM THE PRESIDENT: Gerald Robbins, MD

A special thanks is extended to ASH for their contribution to FLASCO for co-sponsoring a Highlights of ASH earlier this year.

CLINICAL PRACTICE COMMITTEE: Thomas Gaddis, MD, Chairman

Billing of the subq. injection code 96372. (Source: Michelle Smith Flowers, OMF)

Beginning January 1st, 2009, 90772 was changed to 96372 and when billing for two (2) injections (ex. procrit and neupogen) you were to bill for 96372 on two separate lines as well as the drugs being used, no modifiers were to be added to 96372. Many practices were having issues. Thanks to the efforts of Michelle Smith Flowers working with FCSO, resolution has been achieved effective September 30th, 2009.

In order to understand how this issue has been resolved, you need to know some of the processes FCSO has in place when processing claims for billing for more than one drug administered via subq. injection.

According to the customer service manager, every claim that comes through for 2 subq. injections with 2 drugs **WILL REQUIRE MANUAL REVIEW**. This should not cause a problem with processing if the claims examiner follows the instructions and confirms 2 drugs were administered, diagnosis codes are appropriate etc. There apparently was a problem in getting everyone to understand and follow the instructions concerning this billing scenario. BEEN

WHAT TO DO IF YOU HAVE S PREVIOUSLY DENIED CLAIMS FOR 96372??? If you have only 3 or 4 claims in this situation, you can call customer service and have them reprocessed. IF you have numerous claims that require reprocessing, contact customer service and ask for a confirmation number that you will include on the Clerical Reopening form prior to faxing (you can do 10 claims per form).

FCSO UPDATES:

Correction to the LCD for ESA:

FCSO wanted to let you know that they will be posting a corrected article for the ESA LCD that was just put on their website related to the coding changes for ICD-9 2010.

The article titled J0881: Erythropoiesis stimulating agents--clarification on coding (LCD L29168) has an error on page 3. It states Contractors are instructed, per CR 5818 to deny ESA services that report HCPCS codes J0881 or J0885 with an EA modifier when Hgb is <10.0g/L or the Hct is <30%

It should read when Hgb is >10.0g/L or the Hct is >30%.

Intravitreal bevacizumab (Avastin®) – Revision to LCD

The local coverage determination (LCD) for intravitreal bevacizumab (Avastin®) was effective for services provided on or after June 30, 2009. Since that time, the LCD has been revised in accordance with CMS Transmittal 1810, Change Request 6617, dated September 1, 2009, the “CPT/HCPCS Codes” section of the LCD has been revised to delete HCPCS code J3490 (unclassified drugs) and replace it with HCPCS code Q2024 (Injection, bevacizumab, 0.25 mg).

The LCD “Coding Guidelines” attachment has been revised to indicate HCPCS code Q2024 (Injection, bevacizumab, 0.25 mg) is used to appropriately describe smaller doses that total less than 10 mg of bevacizumab (Avastin®). This smaller dose should be billed for the Food and Drug Administration (FDA) approved treatment of metastatic colorectal cancer (i.e., ICD-9-CM codes 153.0-153.9, 154.0-154.3, 154.8, 197.5). HCPCS code Q2024 (Injection, bevacizumab, 0.25

mg) should also be billed for intravitreal bevacizumab, along with CPT code 67028 (*Intravitreal injection of a pharmacologic agent*).

This LCD revision is effective for services provided **on or after October 1, 2009**. First Coast Service Options Inc. (FCSO) LCDs are available through the CMS Medicare Coverage Database. Coding Guidelines for an LCD (when present) may be found by selecting “LCD Attachments” in the “Jump to Section” drop-down menu at the top of the LCD page. For LCDs with a future effective date, select the “Display Future Effective Documents” link at the top of the list of LCDs page.

Zoledronic Acid – Revision to LCD

The local coverage determination (LCD) for zoledronic acid was last revised on June 30, 2009. Since that time, the Food and Drug Administration (FDA) approved a new indication for zoledronic acid (Reclast®), HCPCS code J3488, effective May 29, 2009. This new indication is for the prevention of osteoporosis in postmenopausal women.

The “Indications and Limitations of Coverage and/or Medical Necessity,” “ICD-9 Codes that Support Medical Necessity,” “Utilization Guidelines,” and the “Coding Guidelines” attachment have all been revised to allow for coverage of this new indication. When billing for this new indication, providers will be required to bill ICD-9-CM code V49.81 (Asymptomatic postmenopausal status [age-related] [natural]).

This LCD revision is effective for services provided **on or after May 29, 2009**, for claims processed on or after October 19, 2009. First Coast Service Options Inc. LCDs are available through the CMS Medicare Coverage Database. Coding Guidelines for an LCD (when present) may be found by selecting “LCD Attachments” in the “Jump to Section...” drop-down menu at the top of the LCD page. For LCDs with a future effective date, select the “Display Future Effective Documents” link at the top of the list of LCDs page.

77371: Stereotactic radiosurgery and body radiation therapy -- coding guidelines

Modified: 10/22/2009 Location: FL, PR, USVI Line of Business: Part B Coding guidelines have been developed for the stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) local coverage determination. **Please see separate attachment to this fax blast.**

UNITED HEALTHCARE:

Free Access to NCCN Compendium™

UnitedHealthcare is now offering in-network physicians and their staffs free access to the National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium (TM). The NCCN Compendium is recognized by the Centers for Medicare & Medicaid Services (CMS) as a mandated reference for oncology coverage policy.

To use the NCCN Compendium free of charge, physicians or other health care professionals in UnitedHealthcare's network just need to log on to UnitedHealthcare's dedicated physician Web site, www.unitedhealthcareonline.com, and register and waive the \$499 subscription fee. Once signed up, physicians and their staffs will have unlimited access to the NCCN Compendium.

FDA UPDATES:

FDA Approves New Treatment for Chronic Lymphocytic Leukemia (GlaxoSmithKline)

The U.S. Food and Drug Administration has approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow. Arzerra is approved for patients with CLL whose cancer is no longer being controlled by other forms of chemotherapy.

The product was approved under the FDA's accelerated approval process, which allows earlier approval of drugs that meet unmet medical needs. The accelerated approval process requires further study of the drug. The manufacturer is currently conducting a clinical trial in CLL patients to confirm that the addition of Arzerra to standard chemotherapy delays the progression of the disease.

FLORIDA MEDICAID:

DCF Provider View Link

Providers can now access customer Medicaid coverage information on-line through the Department of Children and Families (DCF) Provider View application. This application provides a link to the DCF My ACCESS Account System

where providers can search and view Medicaid recipient coverage information. For more information, you may view and download the DCF Provider View System Guide at <http://www.dcf.state.fl.us/ess/docs/MYACCESSAccountProviderView.pdf>

MLM UPDATES:

New:

MM6699 – Coverage of Inpatient Rehabilitation Services

<http://www.cms.hhs.gov/MLNMattersArticles/downloads/MM6699.pdf>

Revised:

MM6632 – FDG PET for Solid Tumors and Myeloma

<http://www.cms.hhs.gov/MLNMattersArticles/downloads/MM6632.pdf>

PROGRAM COMMITTEE UPDATES: Jose Lutzy, MD, Chairman

FLASCO Fall Meeting

The FLASCO Fall Meeting will be held at the Tampa Airport Marriott Hotel on November 6-7, 2009. The Program Committee has put together a great agenda for this meeting. **PLEASE MAKE EVERY EFFORT TO ATTEND. SEND IN YOUR REGISTRATION FORM IMMEDIATELY.**

2010 PA/NP Conference:

We are pleased to announce that FLASCO will sponsor its Second Annual Conference for PAs/NPs on March 26, 2010, in Miami. Special thanks are extended to Dayne Alonso, PA-C and Michele Taffaro Neskey, PA-C for agreeing to serve as Co-Chairmen of the Workgroup to plan this Conference.

A Multidisciplinary Approach to Cancer Care: Breast and Colorectal Cancer Treatments:

FLASCO is co-sponsoring this conference along with IMER and the Moffitt Cancer Center. It will be held at the H. Lee Moffitt Cancer Center and Research Institute on December 4 and 5, 2009. This 2-day regional CE conference will provide oncology nurse practitioners and physician assistants with a comprehensive overview of how an interdisciplinary team can manage breast and colorectal cancers, and optimize patient outcomes.

Participate in one or BOTH days. To register visit:

Day 1 (Breast Cancer): www.IMERonline.com/352_bc

Day 2 (Colorectal Cancer): www.IMERonline.com/348_crc

ASCO Elections:

REMINDER - ASCO elections are now open for eligible members (Active, Junior Active and Emeritus) – Voting closes on November 24, 2009– **Please be sure to vote!** (www.asco.org) or direct link:

<http://www.asco.org/ASCOv2/About+ASCO/2010+Election>

Candidates include:

President-Elect

Michael P. Link, MD – Sanford University School of Medicine
Gregory H. Reaman, MD – George Washington Univ. School of Medicine

Nominating Committee:

(2 open seats)

Rogerio C. Lilenbaum, MD - Mt. Sinai Medical Center – Miami Beach
Howard A. Burris, III, MD – Sarah Cannon Research Inst.
Roy S. Herbst, MD, Ph.D – Univ. of Texas MD Anderson Cancer Center
Bruce Minsky, MD – University of Chicago

Board of Directors

Community Oncologist

Therese M. Mulvey, MD - Southcoast Centers for Cancer Care , Mass.
Robin T. Zon, MD, FACP - Michiana Hematology-Oncology, P.C., Ind.

Medical Oncologist

James L. Abbruzzese, MD – Univ. of Texas M.D. Anderson Cancer Center

William John Grandishar, MD – Northwestern University

Non-US Oncologist

David L. Khayat, MD, PhD - France

Frances A. Shepherd, MD, FRCPC – Univ of Toronto

Radiation Oncologist

Stephen M. Hahn, MD – Univ. of Pennsylvania

Lori J. Pierce, MD – University of Michigan

Undesignated Specialty

Carolyn D. Runowicz, MD – Univ. of Connecticut Health Center

Julie M. Vose, MD – Univ. of Nebraska Medical Center

EDUCATIONAL OPPORTUNITIES:

Breast Cancer Educational Programs:

In recognition of National Breast Cancer Awareness Month, AstraZeneca is proud to offer a series of live and archived on-demand programs led by nationally recognized breast cancer experts. Live programs afford you the opportunity to interact with these experts, while on-demand programs can be accessed at your convenience. Please visit www.hormonalaspectsofbc.com to register for these and other programs.

Sanofi-Aventis Oncology – Educational Webinar Program:

Wednesday, November 11, 2009 - 12:00 Noon or 3:30 P.M. – Please sign on 15 minutes prior to each session

Web Meeting Information:

<https://www.webmeeting.att.com>

Meeting# is 8774558695 or 8655408745

Participant Code: 419871

Dial-in Information: Dial-in: 877-455-8695 Participant code: 419871

Topic: 2009 Healthcare Reform and Policy

Please RSVP at your earliest convenience to Ellen Berezna via email ellen.berezna@sanofi-aventis.com

CORPORATE MEMBERSHIP/SPONSORSHIP: (January 1 – December 31, 2009)

FLASCO Members extend a big thanks to all of our 2009 Corporate Members/Sponsors (Companies listed below have either paid 2009 dues or have submitted letters of intent)

PLATINUM

AMGEN
Bayer/Onyx
Cephalon Oncology
Eli Lilly
Oncology Supply/ION
Sanofi-Aventis
Celgene
Eisai, Inc.
Ortho Biotech
Genentech
GlaxoSmithKline
The Phipps Wealth
Management Group
Novartis
Astra Zeneca
Pfizer

GOLD

Abraxis Oncology
Bristol Myers Squibb
Genomic Health
Wyeth
Roche
Millennium
Allos Therapeutics, Inc.
ImClone

SILVER

OSI Pharmaceuticals
US Oncology

BRONZE

Genzyme

FLASCO MEETINGS:

November 6-7, 2009 – FLASCO Fall Meeting – Tampa Airport Marriott Hotel

March 5-6, 2010 – FLASCO Spring Meeting and Annual Session – Tampa Airport Marriott Hotel

March 26, 2010 – PA/NP Conference – Miami

FLASCO CO-SPONSORED MEETINGS:

January 16, 2010 - Clinical Breakthroughs & Challenges in Hematologic Malignancies – Grand Floridian Resort – Lake Buena Vista - For more information, call (813) 745-1247 or e-mail: Melissa.Pearson@MOFFITT.org

OTHER MEETINGS/WEBCASTS

Nov 1-5, 2009 - ASTRO's Annual Meeting – Chicago
November 13 - 15, 2009 - Oncology Nursing Society Fall (ONS) – Tampa
December 5-8, 2009 - ASH Annual Meeting – Ernest N. Morial Convention Center, New Orleans, LA – For more information: <http://hematology.org/meetings/2009/index.cfm>
December 10 - 13, 2009 - San Antonio Breast Cancer Symposium (SABCS) San Antonio, TX
Feb 25-27, 2010 - American College of Radiation Oncology Annual Meeting – Lake Buena Vista, FL
March 17-20, 2010 - ACCC's 36th Annual National Meeting - -Baltimore Marriott Waterfront

FLASCO Contact Info:

Dorothy Green Phillips, Executive Director - Phone: 1.813.349.4410 – Dorothy.Green@cancer.org